PCSK9 and myocardial infarction: During 2017–2018, two pivotal trials demonstrated that PCSK9 inhibitors, when used in conjunction with high-dose statins, can achieve further reductions in low-density lipoprotein (LDL) cholesterol levels and subsequently decrease the incidence of vascular incidents, including ischemic stroke and myocardial infarction (5, 6).